4-{[(tert-butoxycarbonyl)amino]methyl}-4'-hydroxy-1,1'-biphenyl | 848853-15-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-{[(tert-butoxycarbonyl)amino]methyl}-4'-hydroxy-1,1'-biphenyl
• 英文别名: tert-butyl N-(4'-hydroxybiphenyl-4-ylmethyl)carbamate；tert-butyl N-{[4-(4-hydroxyphenyl)phenyl]methyl}carbamate；tert-butyl N-[[4-(4-hydroxyphenyl)phenyl]methyl]carbamate
• CAS: 848853-15-6
• 化学式: C₁₈H₂₁NO₃
• 分子量: 299.37
• InChiKey: WAAADMBOIWYCEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-{[(tert-butoxycarbonyl)amino]methyl}-4'-hydroxy-1,1'-biphenyl 在 benzyltrimethylammonium tribromide 、 calcium carbonate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 以59%的产率得到tert-butyl (3'-bromo-4'-hydroxy[1,1'-biphenyl]-4-yl)methylcarbamate
  参考文献：
  名称：

  [EN] BIPHENYLOXY-ACIDS
  [FR] ACIDES BIPHENYLOXY

  摘要：

  本发明一般涉及取代联苯氧基酸（例如4'-芳基酰胺基联苯基-4(3)-氧基酸和4’-芳基酰胺基甲基联苯基-4(3)-氧基酸）及其使用方法。

  公开号：

  WO2005030702A1
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 三乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 19.17h， 以22%的产率得到4-{[(tert-butoxycarbonyl)amino]methyl}-4'-hydroxy-1,1'-biphenyl
  参考文献：
  名称：

  [EN] BIPHENYLOXY-ACIDS
  [FR] ACIDES BIPHENYLOXY

  摘要：

  本发明一般涉及取代联苯氧基酸（例如4'-芳基酰胺基联苯基-4(3)-氧基酸和4’-芳基酰胺基甲基联苯基-4(3)-氧基酸）及其使用方法。

  公开号：

  WO2005030702A1

文献信息

• Purinenucleoside derivative modified in 8-position and medical use thereof
  申请人：Tatani Kazuya

  公开号：US20070179115A1

  公开（公告）日：2007-08-02

  The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; R A is a hydrogen atom or a hydroxyl group; R 1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R 2 to R 4 , P 1 and Q represents a halogen atom, a cyano group or the like.

  本发明提供了一种用于与血浆尿酸水平异常相关疾病的8-修饰嘌呤核苷衍生物。以下式（I）所代表的一种8-修饰嘌呤核苷衍生物、其前药或药用盐、或其水合物或溶剂化合物，对于痛风、高尿酸血症、尿路结石、高尿酸性肾病等的预防或治疗具有用处。在该式中，n为1或2；RA是氢原子或羟基；R1是氢原子、羟基、硫醇基、氨基或氯原子；环J代表可选地取代的2-萘基，或由以下一般式（II）所代表的基团，其中Y代表单键或连接基团；环Z代表可选地取代的芳基或杂环芳基等；而R2至R4、P1和Q代表卤素原子、氰基或类似物。
• Biphenyloxy-acids
  申请人：Commons Joseph Thomas

  公开号：US20060020003A1

  公开（公告）日：2006-01-26

  The present invention relates generally to substituted biphenyloxy acids (such as 4′-aryl-amido-biphenyl-4(3)-yloxy-acids and 4′-aryl-amidomethyl-biphenyl-4(3)-yloxy-acids) and methods of using them.

  本发明涉及替代联苯氧基酸（例如4'-芳基酰胺联苯基-4（3）-氧基酸和4'-芳基酰胺甲基联苯基-4（3）-氧基酸）及其使用方法。
• PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF
  申请人：Tatani Kazuya

  公开号：US20100249054A9

  公开（公告）日：2010-09-30

  The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; R A is a hydrogen atom or a hydroxyl group; R 1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R 2 to R 4 , P 1 and Q represents a halogen atom, a cyano group or the like.

  本发明提供了一种8-修饰嘌呤核苷衍生物，用于与血浆尿酸水平异常相关的疾病。公式（I）所表示的8-修饰嘌呤核苷衍生物，其前体药物或其药学上可接受的盐，或其水合物或溶剂化物，可用于痛风、高尿酸血症、泌尿系结石、高尿酸性肾病等的预防或治疗。在公式中，n为1或2；RA是氢原子或羟基；R1是氢原子、羟基、硫醇基、氨基或氯原子；环J表示可选取的2-萘基团，或由以下通式（II）所表示的基团，其中Y表示单键或连接基团；环Z表示可选取的芳基团或杂环芳基团等；R2到R4、P1和Q表示卤素原子、氰基或类似物。
• PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1813623A1

  公开（公告）日：2007-08-01

  The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; RA is a hydrogen atom or a hydroxyl group; R1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R2 to R4, P1 and Q represents a halogen atom, a cyano group or the like.

  本发明提供了一种 8-修饰嘌呤核苷衍生物，可用于治疗与血浆尿酸水平异常有关的疾病。下式(I)代表的8-修饰嘌呤核苷衍生物、其原药或其药学上可接受的盐，或其水合物或溶解物可用于预防或治疗痛风、高尿酸血症、尿路结石、高尿酸血症肾病或类似疾病。 式中，n 是 1 或 2；RA 是氢原子或羟基；R1 是氢原子、羟基、硫醇基、氨基或氯原子；环 J 代表任选取代的 2-萘基，或下式通式（II）所代表的基团，其中 Y 代表单键或连接基团；环 Z 代表任选取代的芳基或杂芳基或类似基团；以及 R2 至 R4、P1 和 Q 代表卤素原子、氰基或类似基团。
• Hepatitis B core protein modulators
  申请人：Assembly Biosciences, Inc.

  公开号：US10766890B2

  公开（公告）日：2020-09-08

  The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

  本公开内容部分提供了对乙型肝炎病毒 Cp 具有异生效应特性的化合物。本文还提供了治疗病毒感染（如乙型肝炎）的方法，包括向有需要的患者施用所公开的化合物。